The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
Powered by the Equifax Cloud™ and Patented EFX.AI Capabilities, Optimal Path Gives Organizations a Powerful Tool to Help U.S. Consumers Advance Financial Health and Achieve Personalized Credit Score ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results